Securities & Exchange Commission of Pakistan

Triumph Appoints Tim Valdez President of Factoring Division

Retrieved on: 
Tuesday, December 13, 2022
Securities & Exchange Commission of Pakistan, Annual report, BANK, DBA, NOT, Security (finance), All rights reserved, Insurance, Interstate Insurance Product Regulation Commission, FDIC, Transport, Risk, Service, SSB, Management, Financial services, Bank, Triumph

DALLAS, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Triumph , a member of the Triumph Financial, Inc. (Nasdaq: TFIN) portfolio of brands and a leading provider of working capital financing solutions to the transportation industry, announced today the appointment of Tim Valdez as president of its factoring division.

Key Points: 
  • DALLAS, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Triumph , a member of the Triumph Financial, Inc. (Nasdaq: TFIN) portfolio of brands and a leading provider of working capital financing solutions to the transportation industry, announced today the appointment of Tim Valdez as president of its factoring division.
  • Our goal is for Triumph to thrive as a factoring company and for the entire transportation factoring industry to thrive.
  • His experience there, plus decades in the factoring industry, makes him the ideal leader for Triumph and an ambassador for the entire transportation factoring industry.”
    Prior to joining TriumphPay last year, Valdez worked at WEX Fleet One Factoring, where he managed the daily operations of its transportation factoring portfolio.
  • Factoring products and services offered by Triumph Financial Services LLC, a subsidiary of TBK Bank, SSB, DBA Triumph.

Apollo Commercial Real Estate Finance, Inc. Declares Quarterly Common Stock Dividend

Retrieved on: 
Tuesday, December 13, 2022
NYSE, Apollo Global Management, Security (finance), ARI, Investment, COVID-19, Securities & Exchange Commission of Pakistan

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Apollo Commercial Real Estate Finance, Inc. (the “Company”) (NYSE:ARI) today announced the Board of Directors declared a dividend of $0.35 per share of common stock, which is payable on January 13, 2023 to common stockholders of record on December 30, 2022.

Key Points: 
  • NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Apollo Commercial Real Estate Finance, Inc. (the “Company”) (NYSE:ARI) today announced the Board of Directors declared a dividend of $0.35 per share of common stock, which is payable on January 13, 2023 to common stockholders of record on December 30, 2022.
  • About Apollo Commercial Real Estate Finance, Inc.
    Apollo Commercial Real Estate Finance, Inc. (NYSE: ARI) is a real estate investment trust that primarily originates, acquires, invests in and manages performing commercial first mortgage loans, subordinate financings and other commercial real estate-related debt investments.
  • Forward-looking statements are subject to substantial risks and uncertainties, many of which are difficult to predict and are generally beyond the Company's control.
  • These forward-looking statements include information about possible or assumed future results of the Company's business, financial condition, liquidity, results of operations, plans and objectives.

Partners Bancorp Announces Completion of CEO Transition

Retrieved on: 
Thursday, December 8, 2022
Plata, Securities & Exchange Commission of Pakistan, Liberty Bell Bank, Employment, Security (finance), Bank, Risk, III, Senior, Management

SALISBURY, Md., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Partners Bancorp (NASDAQ: PTRS) (the “Company”), the parent company of The Bank of Delmarva, Seaford, Delaware, and Virginia Partners Bank, Fredericksburg, Virginia, announced that, as planned, John W. Breda has succeeded Lloyd B. Harrison, III as Chief Executive Officer of the Company (the “CEO Transition”).

Key Points: 
  • SALISBURY, Md., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Partners Bancorp (NASDAQ: PTRS) (the “Company”), the parent company of The Bank of Delmarva, Seaford, Delaware, and Virginia Partners Bank, Fredericksburg, Virginia, announced that, as planned, John W. Breda has succeeded Lloyd B. Harrison, III as Chief Executive Officer of the Company (the “CEO Transition”).
  • The CEO Transition was completed in accordance with the terms of Mr. Breda’s and Mr. Harrison’s employment agreements with the Company, as amended.
  • “On behalf of the Board of Directors, I want to thank Lloyd for his excellent service as the Company’s CEO and his leadership following the combination of Virginia Partners Bank and The Bank of Delmarva that created Partners Bancorp,” said Jeffrey F. Turner, Chairman of the Company’s Board of Directors.
  • In Maryland, Virginia Partners Bank trades under the name Maryland Partners Bank (a division of Virginia Partners Bank), and operates a full service branch and commercial banking office in La Plata, Maryland and a Loan Production Office in Annapolis, Maryland.

Clean Energy Technologies (CETY) Announces Plans To List Its Shares On NASDAQ

Retrieved on: 
Wednesday, December 7, 2022
Acquisition, EPC, Section, Electricity, Biochar, News, Communication, Waste, EnergySolutions, Stock, OTC Markets Group, Sale, Overalls, Biomass, Harbor, The Act, FINRA, Prospectus, Consultant, Name, OTCQB, Growth, Securities & Exchange Commission of Pakistan, Engineering, procurement, and construction, Kings Oak, St. Louis, Agriculture, Form, Security (finance), LNG, Engineering

Costa Mesa, California, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Clean Energy Technologies, Inc. (OTCQB:CETY) (“CETY” or the “Company”) a clean energy company offering products and solutions in the renewable and energy efficiency markets announced today that the Company has initiated necessary actions to list its shares on the NASDAQ Stock Market (“NASDAQ”) under the anticipated symbol “CETY.”

Key Points: 
  • Headquartered in Costa Mesa, California, Clean Energy Technologies (CETY) plans to become a leader in the zero emission revolution by offering recyclable energy solutions, clean energy fuels and alternative electric power for small and mid-sized projects in North America, Europe, and Asia.
  • The Company's principal products are Waste Heat Recovery Solutions using our patented Clean CycleTM generator to create electricity.
  • Waste to Energy Solutions converting waste products created in manufacturing, agriculture, wastewater treatment plants and other industries to electricity and BioChar.
  • Engineering, Consulting and Project Management Solutions providing expertise and experience in developing clean energy projects for municipal and industrial customers and Engineering, Procurement and Construction (EPC) companies.

Global Asset Purchase Partnering Terms and Agreements Analysis Report 2022: How and Why Companies Enter Business, Product, Technology and Royalty Asset Deals - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 15, 2022
Biotechnology, Health Technology, Pharmaceutical, Health, Confidentiality, Acquisition, Securities & Exchange Commission of Pakistan, Common, Record, Sale, Intellectual property, Insight, Risk management, Security (finance), Real estate, Bookkeeping, Lease, Petroleum, Property management, Practice of law, Pharma

The "Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015 to 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015 to 2022" report has been added to ResearchAndMarkets.com's offering.
  • The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2015-2022 report provides comprehensive access to available records for over 1,100 asset purchase deals, including contract documents where available.
  • The report provides access to asset purchase deal payment terms as announced between the parties.
  • The report focuses on four primary types of asset available for purchase:
    Business assets - the most common asset exchanging hands.

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Report 2022: Gain an Understanding and Analysis of How and Why Companies Enter Joint Venture Deals - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Pharmaceutical, Health, Medical Devices, Appendix, Biotechnology, Mecum Dealmakers, Chapter Five, Drug development, Chapter Three, Chapter One, A-Z, Chapter Four, Securities & Exchange Commission of Pakistan, Confidentiality, Chapter Six, Insight, Intellectual property, Orientation, It Takes Two, Risk, Motor vehicle, Risk management, Airline, Real estate, Lease, Petroleum, Property management, Practice of law, Joint

The "Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.
  • This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.
  • The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Global Cancer Vaccine Partnering Terms and Agreements Report and Directory 2022: Contract Documents for Over 350 Deals - Trends, Key Players, Top Deal Values, and Deal Financials 2010-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 13, 2022
Pharmaceutical, Health, Oncology, Hyperlink, Mecum Dealmakers, Chapter Five, Chapter Three, Sale, Chapter One, Cancer vaccine, Research, A-Z, Chapter Four, Securities & Exchange Commission of Pakistan, Confidentiality, Agreement, Chapter Six, Record, Intellectual property, Orientation, It Takes Two, Pharmaceutical industry, Publishing, Property management, Vaccine, Lease, Petroleum, Practice of law

The "Global Cancer Vaccine Partnering Terms and Agreements 2010-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Vaccine Partnering Terms and Agreements 2010-2022" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cancer Vaccine Partnering Terms and Agreements 2010-2022 report provides comprehensive access to available deals and contract documents for over 350 Cancer Vaccine deals.
  • The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.
  • In Global Cancer Vaccine Partnering Terms and Agreements 2010-2022, the available deals are listed by:

Marathon Asset Management Closes Inaugural Aircraft Securitization

Retrieved on: 
Tuesday, December 13, 2022
Professional Services, Aerospace, Manufacturing, Finance, Security (finance), Aircraft, Marathon, Airbus, Transport, Environment, Marathon Asset Management, Head, MAST, Research, Investment, Mizuho, Aviation, Business development, Securities & Exchange Commission of Pakistan, Airline, Financial services, Boeing

Marathon Asset Management, L.P., a global credit manager, today announced the closing of MAST 2022-1, its inaugural aircraft securitization.

Key Points: 
  • Marathon Asset Management, L.P., a global credit manager, today announced the closing of MAST 2022-1, its inaugural aircraft securitization.
  • Marathons aviation finance strategy targets the most in-demand commercial aircraft, specifically new-technology and in-production aircraft on lease to the airline industry.
  • Our aircraft team has continued to invest through the cycle, with a focus on in-demand equipment on triple net lease.
  • Marathon Asset Management, L.P. is a New York-based global investment advisor with over $20 billion of capital under management as of June 30, 2022.

Ascent Solar Technologies Hires Paul Warley Jr. as CFO

Retrieved on: 
Monday, December 12, 2022
Environment, Other Energy, Utilities, Aerospace, Manufacturing, Alternative Energy, Energy, Agriculture, Natural Resources, Trust, Security (finance), Army of the United States, Food, Financial Industry Regulatory Authority, ASTI, Life, Bank of America, IP, Bank, CFO, CIGS, Research, Primary energy, PV, Financial management, Bankers Trust, Multimedia, GE Capital, Securities & Exchange Commission of Pakistan, Renewable energy, Management, Ascent Solar, Citadel

Ascent Solar Technologies , Inc. (NASDAQ: ASTI) the leader in designing and manufacturing state-of-the-art, lightweight, flexible thin-film photovoltaic (PV) solutions has hired Paul Warley Jr. as its next chief financial officer (CFO).

Key Points: 
  • Ascent Solar Technologies , Inc. (NASDAQ: ASTI) the leader in designing and manufacturing state-of-the-art, lightweight, flexible thin-film photovoltaic (PV) solutions has hired Paul Warley Jr. as its next chief financial officer (CFO).
  • Warley comes to Ascent Solar with significant experience in corporate turnarounds, restructuring, cross-border trade and capital advisory.
  • View the full release here: https://www.businesswire.com/news/home/20221212005225/en/
    Ascent Solar CFO Paul Warley (Photo: Business Wire)
    Prior to Ascent, Warley was president of Warley & Company LLC, a strategic advisory firm from 2015 to 2022 providing executive management services, capital advisory, and M&A to middle-market companies in the service, construction, technology, oil & gas, clean energy, food, retail and green-building sectors.
  • We would like to thank our outgoing CFO, Mike Gilbreth, for his efforts and the results achieved during his tenure, said Ascent Solar CEO Jeffrey Max.

Global Pharma, Biotech & Diagnostics Co-promotion and Co-marketing Partnering Terms and Agreements Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Biotechnology, Marketing, Health, Communications, Pharmaceutical, Biotechnology, Actavis, Biogen, Novartis, Bausch Health, Amgen, Kyowa Hakko Kirin, Research, Roche, AstraZeneca, Eli Lilly, Baxter, Securities & Exchange Commission of Pakistan, J&J, Confidentiality, BMS, Co-marketing, Record, Co-promotion, Intellectual property, GSK, Merck, Availability, Fine chemical, Pharmaceutical industry, Risk management, Real estate, Petroleum, Property management, Practice of law, Pfizer, Bayer, Teva, Astellas Pharma, Takeda

The "Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2015-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2015-2022" report has been added to ResearchAndMarkets.com's offering.
  • The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report provides comprehensive access to records for over 400 co-promotion and co-marketing deals.
  • This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.
  • Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2015 to 2022.